KIORA PHARMACEUTICALS INC Annual Report Summary

I’ve put together this guide to help you understand Kiora Pharmaceuticals’ performance over the past year. My goal is to explain their complex filings in plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Kiora is a clinical-stage biotech company developing small-molecule treatments for rare eye diseases. Because they have no products on the market yet, their value depends entirely on successfully moving their research through FDA-regulated clinical trials.

This year, they focused on two main projects:

• KIO-301: A "photoswitch" drug designed to restore light perception in patients with inherited vision loss. Their ABACUS-2 Phase 2 trial is testing the drug’s safety and ability to improve vision in 36 patients.
• KIO-104: An anti-inflammatory drug for eye swelling. The KLARITY trial began in mid-2024, aiming to treat inflammation without the side effects of long-term steroid use.

2. Financial performance

Kiora earned no revenue this year, as they are still in the research phase. They spent about $8.5 million on research and development, primarily funding clinical trials and regulatory requirements.

The company relies on strategic partnerships to manage costs. Their deal with Thea Open Innovation (TOI) is a key component of their strategy. TOI holds the option to license and commercialize KIO-301 in Europe and the UK. This partnership provides Kiora with non-dilutive funding and access to TOI’s expertise in bringing drugs to market.

3. Major wins and challenges

• The Win: Kiora earned "Orphan Drug Designation" for KIO-301 from U.S. and European regulators. This provides seven years of market exclusivity if approved, tax credits, and over $3 million in saved application fees.
• The Challenge: As a pre-revenue company, Kiora relies entirely on outside funding. If clinical trials are delayed—due to slow patient recruitment or safety issues—the company’s ability to sustain operations is directly impacted.

4. Financial health

Kiora reported approximately $4.2 million in cash and equivalents. With a quarterly burn rate between $1.5 million and $2 million, the company has less than 12 months of runway. Because the company is small, its stock price is often volatile and sensitive to retail investor sentiment.

5. Key risks

• Trial Failure: If KIO-301 or KIO-104 fail their clinical trials, the company may abandon the projects, which would likely cause the share price to drop significantly.
• Dilution: Kiora will likely need to raise more capital in the near future. If they issue new shares to raise this money, it will reduce your ownership percentage in the company.
• Regulatory Hurdles: Even with Orphan Drug status, the FDA may require larger, more expensive trials before granting approval.

6. Future outlook

The next year hinges on two data releases: results from the ABACUS-2 trial and interim data from the KLARITY trial. Positive results are essential to trigger milestone payments from TOI or to attract a larger partner for a potential buyout. Success in these trials is the company’s primary path to long-term survival.

Note: This is a high-risk, high-reward biotech play. When evaluating this opportunity, remember that you are investing in the success of a scientific experiment. Before buying, consider whether your portfolio can handle the volatility inherent in companies that do not yet have a commercial product.